Skip to main content
. 2022 Feb 5;26(7):1918–1931. doi: 10.1111/jcmm.17214

TABLE 2.

Analysis of LY% in ADC patients

LY% No. (%)

Total

(n = 675)

p value

20–50

(n = 392)

<20

(n = 283)

Basic characteristics
Age 0.639
<45 38(9.7) 29(10.2) 67
45–60 168(42.9) 111(39.2) 279

>60

186(47.4) 143(50.5) 329
Sex 0.006**
Male 192(49.0) 169(59.7) 361
Female 200(51.0) 114(40.3) 314
Stage 0.000***
I 57(14.5) 10(3.6) 67
II 38(9.8) 13(4.6) 51
III 68(17.3) 55(19.4) 123
IV 210(53.6) 190(67.1) 400
Unknown 19(4.8) 15(5.3) 34
Smoking status 0.434
Never smoking 243(62.0) 167(59.0) 410
Current or ex‐smoker

149(38.0)

116(41.0)

265

Differentiation 0.000***
Undifferentiated 235(59.9) 210(74.2) 445
Poor 33(8.4) 41(14.5) 74
Moderate 118(30.2) 28(9.8) 146
Well 4(1.0) 1(0.4) 5
Unknown 2(0.5) 3(1.1) 5
Metastasis
Brain 0.135
No 349(89.0) 241(85.2) 590
Yes 43(11.0) 42(14.8) 85
Bone 0.000***
No 321(81.9) 198(70.0) 519
Yes 71(18.1) 85(30.0) 156
Liver 0.007**
No 371(94.6) 252(89.0) 623
Yes 21(5.4) 31(11.0) 52
Adrenal gland 0.008**
No 382(97.4) 264(93.3) 646
Yes 10(2.6) 19(6.7) 29
Lymph node 0.025*
No 192(49.0) 114(40.3) 306
Yes 200(51.0) 169(59.7) 369
Intrapulmonary 0.959
No 343(87.5) 248(87.6) 591
Yes 49(12.5) 35(12.4) 84
Pleural 0.000***
No 340(86.7) 216(76.3) 556
Yes 52(13.3) 67(23.7) 119
Mediastinal 0.045*
No 387(98.7) 273(96.5) 660
Yes 5(1.3) 10(3.5) 15
*

< 0.05, **< 0.01, ***< 0.001. LY%: lymphocyte percentage; ADC: lung adenocarcinoma; poor: poorly differentiated; moderate: moderately differentiated; well: well differentiated.